Clinical trials recruiting for Malignant Melanoma
21
Recruiting trials
13
US states with sites
19
Countries
5%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 2 |
| New Jersey | 2 |
| Virginia | 2 |
| Washington | 2 |
| Arizona | 1 |
| Arkansas | 1 |
| Florida | 1 |
| Georgia | 1 |
| Indiana | 1 |
| Kentucky | 1 |
| Massachusetts | 1 |
| New York | 1 |
Top cities
Fairfax, Virginia 2Hackensack, New Jersey 2Athens, Georgia 1Boston, Massachusetts 1Buffalo, New York 1Elizabethtown, Kentucky 1Fort Wayne, Indiana 1La Jolla, California 1Margate, Florida 1Nashville, Tennessee 1
Self-screener
Recruiting trials
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
- A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
- A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
- AMT-253 in Patients With Advanced Solid Tumours
- An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract
- FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis
- Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
- GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
- Melanoma Metastasized to the Brain and Steroids
- Modified Vaccine for High Risk or Low Residual Melanoma Patients
- Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
- RAPA-201 Therapy of Solid Tumors
- Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
- Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
- The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Video-Tumorboard PLUS
Related conditions
Trials recruiting for Malignant Melanoma often also study these conditions. Each links to its own recruiting-trial list.
Melanoma 487Lung cancer 2180Breast cancer 2239Triple-negative breast cancer 138Colorectal cancer 1359Renal cell carcinoma 28Non-small cell lung cancer 507Head and neck cancer 62Urothelial Carcinoma 29Telemedicine 7
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Malignant Melanoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.